Trial reportDrugs1988
Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.
Trial report in Drugs, 1988. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 99 citations in OpenAlex.
- Concentrations of ceftriaxone (1,000 milligrams intravenously) in abdominal tissues during open prostatectomy.Antimicrobial agents and chemotherapy · 1996Trial
- Penetration of ceftriaxone (1 or 2 grams intravenously) into mediastinal and cardiac tissues in humans.Antimicrobial agents and chemotherapy · 1996Trial
- Double-blind randomized study of 1 g versus 2 g intravenous ceftriaxone daily in the therapy of community-acquired infections.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 1995Trial
- Clinical pharmacokinetics of ceftriaxone.Clinical pharmacokinetics · 1989Trial
- Population pharmacokinetics and dose optimization of ceftriaxone for children with community-acquired pneumonia.European journal of clinical pharmacology · 2020Article
- Microbial aetiology of brain abscess in a UK cohort: Prominent role of Streptococcus intermedius.The Journal of infection · 2020Observational
- Clinical Benefit of Appropriate Empirical Fluoroquinolone Therapy for Adults with Community-Onset Bacteremia in Comparison with Third-Generation-Cephalosporin Therapy.Antimicrobial agents and chemotherapy · 2017Article
- Single-dose intra-procedural ceftriaxone during endoscopic ultrasound fine-needle aspiration of pancreatic cysts is safe and effective: results from a single tertiary center.Annals of gastroenterology · 2017Article
- Review
- Plasma pharmacokinetics and milk levels of ceftriaxone following single intravenous administration in healthy and endometritic cows.Veterinary research communications · 2010Article
- Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.Clinical pharmacokinetics · 2002Review
- Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.Drugs · 2002Review
- Clinical role of protein binding of quinolones.Clinical pharmacokinetics · 2002Review
- Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.Paediatric drugs · 2001Review
- Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.Clinical pharmacokinetics · 2001Review
- Brain Abscess.Current treatment options in neurology · 1999Article
- Efficacies of cefotaxime and ceftriaxone in a mouse model of pneumonia induced by two penicillin- and cephalosporin-resistant strains of Streptococcus pneumoniae.Antimicrobial agents and chemotherapy · 1996Article
- Review
- In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model.Antimicrobial agents and chemotherapy · 1994Article
- Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.PharmacoEconomics · 1994Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since ceftriaxone was first reviewed in the Journal, further studies have confirmed its broad antibacterial spectrum in vitro and extended its clinical documentation in comparative studies with other widely used drugs in infections of the urinary and lower respiratory tract, meningitis in infants and children, uncomplicated gonorrhoea, perioperative prophylaxis in patients undergoing surgery, and in several other types of infection. As in earlier studies, which primarily used a twice-daily dosage regimen, few significant differences were found between therapeutic groups in comparative studies and results have demonstrated the efficacy of once-daily ceftriaxone in all but the most serious infections, such as sole antibiotic therapy in pseudomonal infections. Wider clinical experience has established that ceftriaxone is generally well tolerated. Thus, ceftriaxone now has a well-defined place as an appropriate alternative for the parenteral treatment of a variety of infections due to susceptible organisms, as well as for perioperative prophylaxis of surgery, and may offer advantages of greater convenience over other parenteral antibiotics which are administered more frequently.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.